121 related articles for article (PubMed ID: 9865424)
21. CYP2D6 mRNA expression in circulating peripheral blood mononuclear cells correlates with in vivo debrisoquine hydroxylase activity in extensive metabolizers.
Carcillo JA; Parise RA; Adedoyin A; Frye R; Branch RA; Romkes M
Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):149-159. PubMed ID: 8832907
[TBL] [Abstract][Full Text] [Related]
22. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer.
Arsova-Sarafinovska Z; Matevska N; Petrovski D; Banev S; Dzikova S; Georgiev V; Sikole A; Sayal A; Aydin A; Suturkova L; Dimovski AJ
Cell Biochem Funct; 2008 Oct; 26(7):771-7. PubMed ID: 18646267
[TBL] [Abstract][Full Text] [Related]
23. Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson disease patients and in families.
Lucotte G; Turpin JC; Gérard N; Panserat S; Krishnamoorthy R
Am J Med Genet; 1996 Jul; 67(4):361-5. PubMed ID: 8837703
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
25. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.
Hsing AW; Gao YT; Wu G; Wang X; Deng J; Chen YL; Sesterhenn IA; Mostofi FK; Benichou J; Chang C
Cancer Res; 2000 Sep; 60(18):5111-6. PubMed ID: 11016637
[TBL] [Abstract][Full Text] [Related]
26. Identification of the primary gene defect at the cytochrome P450 CYP2D locus.
Gough AC; Miles JS; Spurr NK; Moss JE; Gaedigk A; Eichelbaum M; Wolf CR
Nature; 1990 Oct; 347(6295):773-6. PubMed ID: 1978251
[TBL] [Abstract][Full Text] [Related]
27. Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
Fernández-Santander A; Santiago C; Díez-Durán S; González M; de Castro E; Guijarro J; Bandrés F; Lucia A; Gómez-Gallego F
Hum Psychopharmacol; 2008 Aug; 23(6):533-6. PubMed ID: 18425996
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
[TBL] [Abstract][Full Text] [Related]
29. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
30. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
[TBL] [Abstract][Full Text] [Related]
31. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men.
Margiotti K; Kim E; Pearce CL; Spera E; Novelli G; Reichardt JK
Prostate; 2002 Sep; 53(1):65-8. PubMed ID: 12210481
[TBL] [Abstract][Full Text] [Related]
32. [CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].
Zabrocka M; Woszczek G; Borowiec M; Rabe-Jabłońska J; Kowalski ML
Psychiatr Pol; 1999; 33(1):91-100. PubMed ID: 10786218
[TBL] [Abstract][Full Text] [Related]
33. Characterization of cytochrome P450 2D6 alleles using the Invader system.
Nevilie M; Selzer R; Aizenstein B; Maguire M; Hogan K; Walton R; Welsh K; Neri B; de Arruda M
Biotechniques; 2002 Jun; Suppl():34-8, 40-3. PubMed ID: 12083395
[TBL] [Abstract][Full Text] [Related]
34. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
[TBL] [Abstract][Full Text] [Related]
35. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease -- a cohort study.
Teh LK; Zilfalil BA; Marina I; Rosemi BS; Ismail R
J Clin Pharm Ther; 2004 Dec; 29(6):559-64. PubMed ID: 15584944
[TBL] [Abstract][Full Text] [Related]
37. The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women.
Li H; Feng L; Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Li J; Xie Y
Acta Oncol; 2006; 45(5):597-601. PubMed ID: 16864175
[TBL] [Abstract][Full Text] [Related]
38. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
39. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
Tao E; Liu Z; Chen B; Pan X; Shao M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
[TBL] [Abstract][Full Text] [Related]
40. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]